Results 51 to 60 of about 40,088 (308)
Acta Biomedica Scientifica, 2016 Application of zymosan in medicine is limited because of its side effects, since the native granules of zymosan directly activate serum complement components and phagocytic cells.
A. G. Lyubimov +2 more
doaj +1 more source
Activation of the innate immune receptor Dectin-1 upon formation of a 'phagocytic synapse'. [PDF]
, 2011 Innate immune cells must be able to distinguish between direct binding to microbes and detection of components shed from the surface of microbes located at a distance. Dectin-1 (also known as CLEC7A) is a pattern-recognition receptor expressed by myeloid
AM Kerrigan +36 more
core +2 more sources
Experimental Biology and Medicine, 1957 SummaryHeat stable antibodies to zymosan were produced in rabbits and measured by quantitative agglutination. The increased bactericidal activity for Escherichia coli B resulting from injections of zymosan could be absorbed by E. coli B. Some aspects of the antigenicity of zymosan are discussed.
openaire +2 more sources
Modification of Lethality of Endotoxin in Mice by Zymosan
Experimental Biology and Medicine, 1961 SummaryPre-treatment of mice with different preparations of zymosan modified the lethal effect of a subsequent endotoxin challenge, ranging from increased resistance to increased susceptibility, despite equivalent RES stimulation. Source and degree of heating in preparation for injection were determinants. Greater relative sensitivity to i.v. than to i.
Henry H. Freedman, Barnet M. Sultzer
openaire +3 more sources
Nitric Oxide Production and Apoptosis Induction in T Cells through Stimulation of Mesenchymal Stem Cells with Zymosan [PDF]
Journal of Kerman University of Medical Sciences, 2015 Background & Aims: Mesenchymal stem cells (MSCs) are non-hematopoietic multipotant cells, which multiply through attaching to culture plates. Toll-like receptors (TLRs) are inherent immune sensors and regulators of immunomodulatory activities of MSCs ...
Elham darabi +3 more
doaj
FACETS, 2019 Zymosan, an immunogenic cell wall extract of Saccharomyces cerevisiae has potential for use as an experimental pyrogen. However, the short-lived sickness responses noted with intraperitoneal and intra-articular administration of zymosan limits ...
Rachael Dangarembizi +5 more
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023 Background Doxorubicin‐induced myocardial injury is reflected by the presence of vacuolization in both clinical and animal models. The lack of scar tissue to replace the vacuolizated cardiomyocytes indicates that insufficient cardiac inflammation and ...
Guiwen Xu +6 more
doaj +1 more source
A monoclonal antibody recognizing very late activation antigen-4 inhibits eosinophil accumulation in vivo. [PDF]
, 1993 Using an in vivo test system, the role of the β1 integrin very late activation antigen-4 (VLA-4) in eosinophil accumulation in allergic and nonallergic inflammatory reactions was investigated.
Lobb, RR +3 more
core +1 more source
MacMARCKS Mutation Blocks Macrophage Phagocytosis of Zymosan [PDF]
Journal of Biological Chemistry, 1995 A major protein kinase C substrate, MacMARCKS (F52, MPR), was examined for its role in phagocytosis. In macrophage-phagocytosing zymosan particles, MacMARCKS was concentrated around nascent phagosomes as detected by immunofluorescent microscopy. The effector domain of MacMARCKS contains the phosphorylation sites, a calmodulin binding site, as well as a
Jianxun Li, Zhihua Bao, Zixin Zhu
openaire +3 more sources
Dimethyl sulfoxide inhibits zymosan-induced intestinal inflammation and barrier dysfunction.
World Journal of Gastroenterology, 2015 AIM To investigate whether dimethyl sulfoxide (DMSO) inhibits gut inflammation and barrier dysfunction following zymosan-induced systemic inflammatory response syndrome and multiple organ dysfunction syndrome.
Yu-meng Li +6 more
semanticscholar +1 more source